Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (Nasdaq: CSTL) announced that its skin cancer gene expression profile tests will be presented at the 2021 AAD Summer Meeting from Aug. 5-8, 2021. Key presentations include:

• Integrating 31-gene expression profiling: Aug. 7, 1:50-2:02 p.m. by Nicholas Taylor, M.D.
• Risk assessment by the 40-gene expression profile test: Aug. 7, 2:32-2:44 p.m. by Aaron Farberg, M.D.

The tests are designed to improve prognostication for melanoma and cutaneous squamous cell carcinoma.

Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its gene expression profile tests, DecisionDx®-Melanoma and DecisionDx®-SCC, at the DERM2021 conference. DecisionDx-Melanoma predicts metastasis risk using individual tumor data and has shown a 98% negative predictive value in T1-T4 tumors. For DecisionDx-SCC, clinical data emphasizes its reliability (96.3%) and its role in classifying high-risk patients. The studies collectively support enhanced patient management decisions, leveraging genomic information to improve treatment outcomes.

Castle Biosciences (Nasdaq: CSTL) announces continued collaboration with the Melanoma Research Foundation (MRF) to enhance melanoma treatment through research, education, and advocacy. Castle is sponsoring the MRF Miles for Melanoma 5K events across five U.S. cities and the 2021 MRF galas in Chicago, Denver, and New York. MRF has funded over $20.1 million in melanoma research since 1998. Castle's DecisionDx-Melanoma test helps predict melanoma risk, with over 73,396 tests ordered to date, benefiting patient management.

Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The presentation will be available via a live audio webcast on the company’s website, with a replay accessible for two weeks post-event.

Castle Biosciences focuses on dermatologic diagnostics, providing genomic information that informs treatment decisions, particularly for melanoma and other skin cancers. Their innovative tests are designed to aid physicians in making personalized treatment plans.

Castle Biosciences (Nasdaq: CSTL) will release its second quarter financial results on August 9, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The company specializes in dermatologic diagnostics, offering genomic tests for melanoma and other skin cancers to support treatment decisions. Castle aims to enhance personalized medicine experiences for patients and physicians. Additionally, the company has ongoing R&D for psoriasis treatment response testing, and it recently acquired the myPath Melanoma laboratory in Salt Lake City.

Castle Biosciences, Inc. (Nasdaq: CSTL) announced a podium presentation on its DecisionDx®-SCC test at the AHNS 10th International Conference from July 22-25, 2021. This 40-gene expression profile test assesses the metastasis risk in high-risk cutaneous squamous cell carcinoma patients. A study involving 278 patients demonstrated significant differences in three-year metastasis-free survival rates based on the DecisionDx-SCC results compared to traditional staging methods. The test enhances risk assessment and informs treatment decisions.

Castle Biosciences (Nasdaq: CSTL) announced data presentations for two gene expression profile tests, DecisionDx-Melanoma and DecisionDx-SCC, at the SDPA Annual Summer Dermatology Conference 2021. DecisionDx-Melanoma predicts melanoma metastasis and recurrence risk, showing that 89% of nurse practitioners view its testing as beneficial to patient care. DecisionDx-SCC assesses metastatic risk in cutaneous squamous cell carcinoma patients, reporting a technical reliability of 96.3% across the first 1000 samples. Both studies underline the clinical utility of these tests in improving treatment decisions.

Castle Biosciences, Inc. (Nasdaq: CSTL) has appointed Kim Caple and Ellen Goldberg to its board of directors, effective immediately. Derek Maetzold, CEO, expressed confidence in their leadership and experience. Caple, currently with Thermo Fisher Scientific, brings expertise in genetic analysis technologies. Goldberg, founder of CHORD Consulting, has a robust background in diagnostics and marketing, notably with the Oncotype DX Breast Cancer Assay. The company specializes in dermatologic diagnostics, providing genomic information for better treatment decisions.

Castle Biosciences, Inc. (Nasdaq: CSTL) has been recognized in the Houston Chronicle’s CHRON 100 list for the second consecutive year, highlighting its success in Market Value, Market Return, and Revenue Growth. The recognition reflects Castle's ongoing growth in genomic diagnostics for dermatologic conditions, primarily through its flagship product, the DecisionDx®-Melanoma. The firm plans to enhance its diagnostic suite further, contributing to its stature as a leader in the sector and aiming to improve patient outcomes.